This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.
Capmatinib works in patients with lung cancer with a particular mutation in their cancer known as a METex14 skipping mutation.
Investigators now wish to find out if it will be useful in treating patients with other cancer types which have the same mutation or other specific mutations or changes which take place in the MET gene. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.
This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.
None
Have a negative serum or urine pregnancy test before enrolment, and
Agree to take measures not to father children by using a barrier method of contraception (e.g. condom) or sexual abstinence.
Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses a highly effective method of contraception, as in criterion C above.
Male patients with pregnant or lactating partners must be advised to use barrier method contraception (for example, condom) to prevent drug exposure of the foetus or neonate.
Cancer Research UK
Lead sponsor
University of Birmingham
Collaborator
Royal Marsden NHS Foundation Trust
Collaborator
Novartis Pharmaceuticals
Collaborator
University of Manchester
Collaborator